Joint WHO-UNAIDS Statement re HIV information leak

BEIING, 18 July 2016 – The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have been informed of the suspected leak of confidential information about people living with HIV in China over the last week. Chinese health and public security authorities are investigating what appears to be a serious case of fraud, where people posing as government officials contacted people living with HIV and promised they would be provided with financial allowances in exchange for their banking information. Health authorities are also investigating how patient information systems were breached and the personal details of people living with HIV were accessed.

WHO congratulates Beijing, calls for national smoke-free law

Image credit: Commonwealth of Australia

BEIJING, 30 May 2016 – On World No Tobacco Day 2016, the World Health Organization (WHO) congratulates Beijing on one year of successful implementation of its smoke-free law, and is calling on China’s lawmakers to adopt a similar law to apply nation-wide.

Eradication of polio one step closer for China, and the world

WHO/B. Kadirov

BEIJING, 29 April 2016 – The global goal of eradicating polio is one step closer this week, as China along with 154 other countries, make the shift to a new, safer, and more immunogenic polio vaccination schedule – including an unprecedented, globally-synchronized change to ‘switch off’ a now-eradicated strand of polio virus in polio vaccines. This effort will provide better protection for children against polio, particularly those most vulnerable to infection.

Scale of traffic deaths and injuries constitutes ‘a public health crisis’ – Safe roads contribute to sustainable development

BEIJING, 24 May 2016 – Every year, 1.25 million people die from road traffic injuries, and another 20–50 million people sustain nonfatal injuries as a result of road traffic collisions or crashes. Road traffic injuries are a top 10 cause of death globally, and the leading cause of death for people aged 15–29.

“The carnage that occurs on the world’s roads every single day is a public health crisis of gargantuan proportions,” said Dr Bernhard Schwartländer, WHO Representative in China.

Highlights from the country

  • 22 March 2016

    New era of partnership between WHO and China

    On 22 March 2016, WHO Regional Director for the Western Pacific Dr Shin Young-soo and National Health and Family Planning Commission (NHFPC) Minister Li launched the new WHO-China Country Cooperation Strategy (CCS). The CCS outlines the priorities for WHO’s work in China over the next 5 years.

  • 14 March 2016

    WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP): policy brief

    In 2014 WHO recommended offering pre-exposure prophylaxis (PrEP) to men who have sex with men (MSM). On the basis of further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened the recommendation to include all population groups at substantial risk of HIV infection.

    Offering PrEP should be a priority for populations with an HIV incidence of about 3 per 100 person-years or higher. PrEP should be an additional prevention choice in a comprehensive package of services that also includes HIV testing, counselling, male and female condoms, lubricants, ARV treatment for partners with HIV infection, voluntary medical male circumcision and harm reduction interventions for people who use drugs.

  • 14 March 2016

    WHO Technical Consultation on a comprehensive National Hepatitis Programme in China with a focus on viral hepatitis B and C treatment, Beijing, China, 21 February 2014 : meeting report

    China has a heavy burden of viral hepatitis. About 90 million people are chronically infected with the hepatitis B virus and about 7 to 10 million people are estimated to be infected with the hepatitis C virus. The consequence of chronic hepatitis is substantial - liver cancer is the second leading cause of death in China in the agegroup of 35-54 years of age. Effective treatment for hepatitis B and C is available. Studies show that treatment for hepatitis B and C is cost effective, and may reduce death due to chronic hepatitis-related liver disease including liver cancer.

    In view of importance of chronic hepatitis in China, a technical consultation was held on 21 February 2014 in Beijing with national stakeholders to discuss the scientific evidence, current challenges and new opportunities for scaling up hepatitis treatment in China using the public health approach.

WHO work in China

China-WHO Country Cooperation Strategy 2016-2020

WHO China Office-New space for health

Contact information

World Health Organization China Representative Office
401 Dongwai Diplomatic Building,
23 Dongzhimenwai Dajie,
Chaoyang District,
Beijing 100600, PR China
Telephone: +86 10 6532-7189 / 90 / 91 / 92
Fax: +86 10 6532-2359